Slide 1: Results for the year ended 31 December 2020
Results for the year ended 31 December 2020 Andrew Newland and Ian Griffiths 29 April 2021
Slide 2: Legal disclaimer
LSE AIM: AGL OTCQX: ANPCY Legal disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The presentation slides which follow this notice and the oral presentation of whi
Slide 3: Transforming cancer care with a simple blood test
Transforming cancer care with a simple blood test Parsortix® cassette “ANGLE’s mission is to enable personalised cancer care by providing the complete picture of the patient’s cancer from a simple blood test. Our Parsortix® system has the potential to deliver profound improvements in clinical and he
Slide 4: 2020 Highlights
2020 Highlights Significant progress against key strategic objectives • Working practices adapted for COVID-19 • FDA De Novo Submission for Class II clearance in metastatic breast cancer submitted September 2020 – over 15,000 samples and 400 reports / technical documents – successful FDA administrat
Slide 5: Further momentum post year end
Further momentum post year end • Additional Information Request received from FDA – encouraging that AIR received without undue delay – comprehensive response being prepared • Clinical Services Laboratories launched • First large-scale pharma services contract secured • Ovarian cancer clinical verif
Slide 6: Financial Results for year ended 31 December 2020
Financial Results for year ended 31 December 2020 Year ended 31 8 months ended 31 December 2020 December 2019* Comments £’000 £’000 Statement of Comprehensive Income • Revenue reduced by COVID-19 Revenue and grant income 841 642 impact on customers Cost of sales (165) (142) • Gross margin 78% Gross
Slide 7: COVID-19 and cancer – urgent need for liquid biopsy
COVID-19 and cancer – urgent need for liquid biopsy • COVID-19 has caused an unprecedented crisis with impact on cancer diagnosis and care • Urgent priority to end delays and address backlogs in cancer diagnosis and treatment • Information provided by liquid biopsy could help clinicians diagnose, mo
Slide 8: FDA substantive review in process for MBC
FDA substantive review in process for MBC Seeking first ever FDA clearance for a device to harvest Four leading US cancer centres participated cancer cells from patient blood for subsequent analysis • ahead of known competition with five years of clinical • University of Texas MD Anderson Cancer Cen
Slide 9: Prospect of FDA clearance during H2 CY21
Prospect of FDA clearance during H2 CY21 • FDA De Novo Submission for Class II clearance in metastatic breast cancer submitted 25 September 2020 – over 15,000 samples and 400 reports and technical documents – successful FDA administrative review and acceptance for substantive review • Additional Inf
Slide 10: Clinical laboratories established ahead of schedule
Clinical laboratories established ahead of schedule Clinical services laboratories established in US and UK as accelerators and demonstrators • Pharma services and initial clinical services • Offer new tests: – epithelial, EMTing, mesenchymal CTCs and clusters – ER/PR/HER2 application – PD-L1 immuno
Slide 11: First large-scale pharma services contract
First large-scale pharma services contract • Contract secured with oncology focused pharma company with multiple cancer trials ongoing and planned • Parsortix ability to capture mesenchymal CTCs and CTC clusters seen as a key advantage • Initial contract worth up to US $1.2 million over 18 months •
Slide 12: Ovarian cancer test study enrolment completed
Ovarian cancer test study enrolment completed • Clinical verification 200 patient study in progress with the University of Rochester Wilmot Cancer Center • Two 200 patient studies already completed with best in class results AUC >95% accuracy achieved. Potential for high sensitivity and high specifi
Slide 13: Leveraged strategy delivers growing body of evidence
Leveraged strategy delivers growing body of evidence • Installed base of over 200 Parsortix systems in active use Eleven peer-reviewed publications in 2020 • Nine independent cancer centres – Edith Cowan University, Perth, Australia – University Medical Center Hamburg-Eppendorf, Germany – Istituto N
Slide 14: Commercialisation aim to enable entire industry
Commercialisation aim to enable entire industry Product-based commercialisation delivers numerous opportunities • Medtech companies to expand revenue opportunities for installed base – expand from one-off tissue biopsy to repeat liquid biopsy tests • Pharma companies to enable precision medicines –
Slide 15: Near term commercialisation plan
Near term commercialisation plan Leading cancer centres with original research and peer-reviewed publications using ANGLE’s Parsortix system (selection) • Expanding pharma services business • Prospect of FDA clearance H2 CY21* • Ovarian cancer headline results expected Q4 CY21 • Seeking to launch ov
Slide 16: Questions and answers
Questions and answers © ANGLE plc 2021 16
Slide 17: Investment Overview
Investment Overview ANGLE’s Parsortix® system is a simple blood test for personalised cancer Large scale clinical studies in ovarian cancer significantly out-performed care, which harvests viable intact cancer cells (CTCs) for analysis existing standard of care • unique patented microfluidic approac
Slide 18: ANGLE plc contact details
ANGLE plc ANGLE Europe Ltd 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom ANGLE North America Inc 5100 Campus Drive Suite 120 Plymouth Meeting PA 19462 USA ANGLE Biosciences Inc 50 Ronson Drive, Suite 105 Toronto Ontario M9W 1B3 Canada www.angleplc.com 18